Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy.

ABSTRACT:

Background

Gastric cancer (GC) is one of the most common cancer types, especially in Asian countries. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve the progression-free survival among gastric cancer patients with peritoneal metastases; however, not all patients demonstrate response to HIPEC.

Methods

Biomarkers are needed to select patients for effective treatment of HIPEC. Here, we performed whole-exome sequencing on tumor samples from 18 gastric cancer patients who received HIPEC treatment and assessed the association between genomic mutation features and progression-free survival. Exome sequencing was further conducted on tumor samples from additional 15 gastric cancer patients as a replication study.

Results

The tumor mutational burden

SUBMITTER: Zeng L 

PROVIDER: S-EPMC8958003 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature